rupiya.io
⠋Loading...
0%
❯ Pulling quarterly results...
Wockhardt Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Wockhardt Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,482 Cr | ₹4,453 Cr | ₹4,015 Cr | ||||||||
| Expenses | ₹3,772 Cr | ₹3,959 Cr | ₹4,002 Cr | ||||||||
| Operating Profit | ₹709 Cr | ₹494 Cr | ₹13 Cr | ||||||||
| OPM % | 16.0% | 11.0% | 0.0% | ||||||||
| Other Income | ₹67 Cr | ₹66 Cr | ₹114 Cr | ||||||||
| Depreciation | ₹145 Cr | ₹142 Cr | ₹149 Cr | ||||||||
| Interest | ₹55 Cr | ₹129 Cr | ₹225 Cr | ||||||||
| Profit Before Tax | ₹575 Cr | ₹289 Cr | ₹-247 Cr | ||||||||
| Tax | ₹575 Cr | ₹289 Cr | ₹-247 Cr | ||||||||
| Net Profit | ₹413 Cr | ₹252 Cr | ₹-226 Cr | ||||||||
| EPS (₹) | 28.3 | 17.5 | -13.6 | ||||||||
| Dividend Payout % | 54% | 0% | -56% |
Register free to see 8 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹678 Cr | ₹644 Cr | ₹753 Cr | ₹701 Cr | ||||||||
| Expenses | ₹675 Cr | ₹628 Cr | ₹681 Cr | ₹664 Cr | ||||||||
| Operating Profit | ₹3 Cr | ₹16 Cr | ₹72 Cr | ₹37 Cr | ||||||||
| OPM % | 0.0% | 2.0% | 10.0% | 5.0% | ||||||||
| Depreciation | ₹56 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr | ||||||||
| Interest | ₹76 Cr | ₹79 Cr | ₹76 Cr | ₹77 Cr | ||||||||
| Net Profit | ₹-237 Cr | ₹-136 Cr | ₹-73 Cr | ₹-86 Cr | ||||||||
| EPS (₹) | -14.4 | -9.3 | -5.3 | -5.8 |
Register free to see 8 more quarters.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹55 Cr | ₹55 Cr | ₹55 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,362 Cr | ₹3,720 Cr | ₹3,281 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹2,309 Cr | ₹2,677 Cr | ₹4,160 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,213 Cr | ₹1,622 Cr | ₹1,486 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹6,939 Cr | ₹8,074 Cr | ₹8,982 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹2,123 Cr | ₹2,809 Cr | ₹2,773 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹341 Cr | ₹0 Cr | ₹563 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹3,468 Cr | ₹4,228 Cr | ₹4,403 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹6,939 Cr | ₹8,074 Cr | ₹8,982 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 8 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹355 Cr | ₹-222 Cr | ₹-76 Cr | — |
| Mar 2017 | ₹-42 Cr | ₹-105 Cr | ₹193 Cr | — |
| Mar 2018 | ₹-269 Cr | ₹-684 Cr | ₹1,254 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 8 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.